John L. LaMattina, Ph.D.

Board Member

Equibles does not estimate personal net worth.

Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.

Get LGND alerts

About John L. LaMattina, Ph.D.

John L. LaMattina, Ph.D. is recorded as Board Member at Ligand Pharmaceuticals Inc (LGND) since June 5, 2026. Ligand Pharmaceuticals Inc reported in an 8-K filed June 9, 2026 that John L. LaMattina, Ph.D. was appointed director of the Company, effective June 5, 2026. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason Haas (Board Member) and 7 others.

“John L. LaMattina, Ph.D. | 16,714,494 | 819,265 | 1,257,231”

Ligand Pharmaceuticals Inc Form 8-K, filed June 9, 2026 · Read the filing

Affiliation history

Ligand Pharmaceuticals Inc (LGND)
Board Member

SEC 8-K

Current
2026-06-05–present

Company network

Ligand Pharmaceuticals Inc

LGND

Current role

Biotechnology · Healthcare

Board Member

2026-06-05–present

Leadership on record at Ligand Pharmaceuticals Inc

Todd C. Davis CEO, Board Member
Tavo Espinoza CFO
Jason Haas Board Member
Jason M. Aryeh Board Member
Jennifer Cochran, Ph.D. Board Member
John L. LaMattina Board Member
John W. Kozarich Board Member
John W. Kozarich, Ph.D. Board Member
Martine Zimmermann Board Member
Martine Zimmermann, Pharm.D. Board Member

Recent activity

Executive change Appointed: director of the Company Ligand Pharmaceuticals Inc (LGND)
2026-06-05